In the clinical trial Sensor-Augmented Pump Therapy for A@C Reduction ( STAR @ ) , @ adults with type @ diabetes were randomly allocated to either SAP or glargine-based multiple daily injection ( MDI ) therapy at @ US sites ( n = @ ) and @ Canadian sites ( n = @ ) .